Starpharma Holdings Limited (ASX:SPL)

Click Here Starpharma Holdings Limited (ASX:SPL) share price

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP® drug delivery and VivaGel®.

Starpharma is developing VIRALEZE™, an antiviral nasal spray for COVID-19 which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE™ also has potential use in future pandemics and is afforded expedited development because it is repurposing an already-marketed, broad-spectrum antiviral dendrimer, SPL7013. SPL7013 is utilised in approved products – the VivaGel® condom and VivaGel® BV.

VivaGel® BV has been licensed in >160 countries, is approved in >40 countries and available in for sale in the UK, Europe, South East Asia, Australia and New Zealand. As a leading company in dendrimer based drug delivery, Starpharma’s proprietary drug delivery platform technology, DEP®, which is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies.

DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), and other world leading pharmaceutical companies Starpharma’s partnered DEP® programs have the potential to generate significant future milestones and royalties.

Starpharma Holdings appoints Cheryl Maley as Chief Executive Officer and Managing Director

Starpharma signs research agreement with MSD

Leave a Reply

Your email address will not be published. Required fields are marked *